Skip to main content
三元基因 logo

三元基因 — Investor Relations & Filings

Ticker · 920344 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 420 across all filing types
Latest filing 2022-02-17 Major Shareholding Noti…
Country CN China
Listing Beijing Stock Exchange 920344

About 三元基因

http://www.triprime.com/

Beijing Tri-Prime Gene Pharmaceutical Co., Ltd. is a biotechnology enterprise specializing in the research, development, production, and commercialization of modern genetic engineering pharmaceuticals. The company's core focus is on recombinant human interferon products, most notably Interferon ̑1b. This product is widely utilized in the treatment of viral diseases and malignant tumors, with a significant presence in the pediatric respiratory and hepatology markets. Tri-Prime Gene leverages advanced molecular biology and protein purification technologies to maintain its position as a leader in the interferon market. Its portfolio includes various formulations such as injections, sprays, and drops, designed to meet diverse clinical needs. The company continues to invest in innovative biopharmaceuticals, aiming to provide effective therapeutic solutions for infectious diseases and oncology.

Recent filings

Filing Released Lang Actions
持股百分之五以上股东减持股份计划公告
Major Shareholding Notification Classification · 100% confidence The document is a public announcement regarding a shareholder holding more than 5% of shares planning to reduce their holdings. It details the shareholder's identity, the number and percentage of shares to be reduced, the method and timing of the reduction, compliance with stock exchange rules, and risk disclosures related to the share reduction. There is no financial data, earnings information, or management discussion. The content fits the definition of a Major Shareholding Notification, which involves notifying changes in significant share ownership levels crossing thresholds. The document length is short (1590 characters), and it is not an announcement of a report publication but a direct notification of shareholding changes.
2022-02-17 Chinese
股票解除限售公告
Share Issue/Capital Change Classification · 95% confidence The document is a stock-related announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the lifting of trading restrictions on certain shares, including the number of shares, shareholders involved, reasons for lifting restrictions, and the updated share capital structure. The document does not contain financial statements, earnings data, or management discussion. It is not a report but an announcement about share trading status changes. This fits the category of Share Issue/Capital Change (SHA), which covers announcements regarding share issues, stock splits, or capital changes such as lifting share restrictions.
2022-02-15 Chinese
重要临床试验项目取得阶段性成果的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the interim results of a clinical trial project. It provides details about the clinical trial progress, safety and efficacy evaluation, and the recommendation to continue the trial. The document explicitly states that the announcement is about the clinical trial's phase achievements and its impact on the company, emphasizing risk warnings for investors. There is no financial data, no mention of annual or quarterly financial results, no voting results, no management changes, no merger or acquisition activity, and no regulatory certification. The document is relatively short (856 characters) and is an announcement of clinical trial progress, which is a regulatory disclosure but does not fit into financial report categories like Annual Report, Interim Report, or Earnings Release. It is not a report publication announcement since it contains substantive information about the clinical trial progress. The best fitting category is Regulatory Filings (RNS), as it is a general regulatory announcement about clinical trial progress and risk disclosure that does not fit other specific categories.
2022-01-19 Chinese
关于延长公司股东股份锁定期的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Beijing Sanyuan Gene Pharmaceutical Co., Ltd. regarding the extension of the lock-up period for shareholders' shares. It details the lock-up commitments made by controlling shareholders, directors, and senior management following a public offering and listing on the National SME Share Transfer System. The document includes specific shareholder names, share quantities, original lock-up periods, and the extended lock-up periods. There is no financial data, earnings information, or report publication mentioned. The content is a regulatory announcement about shareholder share lock-up extension, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories like capital changes or major shareholding notifications.
2022-01-11 Chinese
北京市浩天信和律师事务所关于三元基因2021年第三次临时股东大会之法律意见书
Regulatory Filings
2021-12-26 Chinese
2021年第三次临时股东大会决议公告
Declaration of Voting Results & Voting Rights Announcements Classification · 95% confidence The document is an announcement of the resolutions passed at the 2021 third extraordinary general meeting of shareholders of Beijing Sanyuan Gene Pharmaceutical Co., Ltd. It details the meeting date, attendance, agenda items, voting results, and legal opinions on the meeting's validity. It does not contain financial statements or detailed financial analysis but rather the official voting results and decisions made at the meeting. This fits the definition of a Declaration of Voting Results & Voting Rights Announcements (DVA). The document length is short (1397 characters), and it is not a report publication announcement or a regulatory filing. Therefore, the correct classification is DVA with high confidence.
2021-12-26 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.